Document:

June 1, 2005

Meridian Commercial Healthcare Finance, LLC
4320 La Jolla Village Drive, Suite 250
San Diego, California 92122

Re:   PracticeXpert of Oklahoma, Inc., and PracticeXpert of Idaho, Inc.
      (each, a "Debtor", and collectively, the "Debtors")

Ladies and Gentlemen:

      The undersigned ("Indemnitor") is entering into this Indemnification
Agreement to induce you to extend financial accommodations to each respective
Debtor pursuant to the terms of a Loan and Security Agreement, each dated as of
June 1, 2005, between such Debtor and you (each, a "Credit Agreement", and
collectively, the "Credit Agreements"). (All obligations of each Debtor to you,
whether pursuant to such Debtor's respective Credit Agreement or otherwise are
hereinafter referred to as the "Obligations".) Any capitalized term not defined
herein shall have the meaning ascribed thereto in the current or any future
California Uniform Commercial Code.

      Indemnitor hereby continuously represents and warrants, that:

      A. Financial Statements. All statements and reports made or to be made to
you by each Debtor or any direct or indirect, absolute or contingent obligor on
the Obligations are and shall remain true and correct.

      B. Borrowing Base Calculations. All calculations of availability of funds
of each Debtor under the respective Credit Agreement between such Debtor and you
shall be correct in all respects.

      C. Accounts.

            i. Each Account of each Debtor (an "Account") is genuine, valid,
subsisting and enforceable in accordance with its terms, is in all respects what
it purports to be, and represents an undisputed and bona fide indebtedness owing
to such Debtor by the Account Debtor.

            ii. Each Account is accepted by the corresponding Account Debtor,
and there are no defenses, setoffs, credits, contras, or counter-claims against,
or disputes with respect to any Account, nor is the payment of any Account
conditioned or contingent upon the fulfillment of any contract, condition or
warranty, past or future, expressed or implied.

            iii. All payments received by each Debtor in payment of any Account
have been deposited, delivered and used only as permitted in the Credit
Agreement with such Debtor.

                                       1
<PAGE>

            iv. Each copy of an invoice delivered to or shown to you in the
course of providing credit accommodations to each Debtor is and shall be a true
and genuine copy of the original sent to the Account Debtor named therein and
accurately reflects all terms of the transaction from which such Account arose,
including but not limited to the amount due and the payment due date (whether
stated on each such invoice, or computed based on the information set forth on
such invoice).

            v. All Chattel Paper, promissory notes, drafts, trade acceptances,
or other instruments for the payment of money, and any endorsements thereon, are
true and genuine and in all respects what they purport to be, and represent the
valid and binding obligation of all parties thereto, and all amounts and dates
stated on all such items are correct.

            vi. Any promissory notes, letters of credit or post-dated checks
received by each Debtor in payment of or as credit support for any Accounts will
be immediately either delivered or reported to you.

            vii. All Inventory described in any invoice has been delivered to an
Account Debtor or placed for such delivery in the possession of a carrier not
owned or controlled directly or indirectly by each Debtor.

            viii. All evidence of the delivery or shipment of Inventory is true
and genuine.

            ix. All services to be performed by each Debtor in connection with
each Account have been performed by such Debtor.

      D. Title to Collateral. Each Debtor:

            i. Is the owner of all collateral heretofore or hereafter pledged by
such Debtor to you (the "Collateral"), free of all security interests, liens or
other encumbrances, except your security interest therein and any other liens
which have been disclosed in writing to you.

            ii. Has the unconditional authority to grant you a security interest
in the Collateral.

            iii. Will not take or fail to take any action (specifically
including but not limited to the suffering of any federal tax lien) which will
adversely affect the priority of your security interest in the Collateral.

            iv. Will not transfer the Collateral, other than the selling or
leasing Inventory in the ordinary course of such Debtor's business.

      Indemnitor indemnifies you from any loss, including any actual,
consequential, incidental or other damage (the amount of which shall be presumed
to be the face amount of any affected invoice, or the greater of cost or market
of any affected Inventory, where such measure of damage shall be appropriate in
your sole discretion) incurred by you as the result of, or arising out of, the
breach of any covenants set forth in Section 8 of each Credit Agreement,
warranties or representations (in whole or part) made by each Debtor or
Indemnitor to you. Indemnitor further indemnifies you against, and agrees to
reimburse you for, all costs and expenses incurred (including reasonable
attorneys' fees) in the negotiation, preparation, administration and/or
enforcement of this Indemnification Agreement.

                                       2
<PAGE>

      Indemnitor's obligations hereunder shall not be affected by, and
Indemnitor waives any and all claims and defenses arising out of, any of the
following:

            o     Any failure to perfect or continue the perfection of any
                  security interest in or other lien upon any Collateral;

            o     The invalidity, unenforceability, impropriety of manner of
                  enforcement of, or loss or change in priority of, any such
                  security interest or lien;

            o     The failure to protect, preserve or insure any Collateral;

            o     Any  failure  of  the   Indemnitor  to  receive   notice  of
                  presentment,  demand, protest, default, non-payment, partial
                  payment,  any intended disposition of any of the Collateral,
                  the  acceptance of this  Agreement or the Credit  Agreements
                  (including  the  acceptance  of any  assignment  of accounts
                  thereunder),  any  extension of credit by you to any Debtor,
                  and  all  other  notices  to  which   Indemnitor   might  be
                  otherwise entitled;

            o     The cessation, from any cause whatsoever, of any Debtor's
                  liability, including, without limitation, any failure,
                  negligence or omission by you in enforcing your claims against
                  such Debtor;

            o     Any release,  settlement or compromise of any  obligation of
                  any Debtor; or

            o     The invalidity or unenforceability of the Obligations.

      This Indemnification Agreement shall remain in full force and effect until
the later to occur of termination of the Credit Agreements or repayment in full
of the Obligations.

      In the event of any litigation arising hereunder, the prevailing party
shall recover its attorney's fees and expenses from the unsuccessful party. Any
action arising hereunder may, at your election, be prosecuted in any court
located in California (the "Acceptable Forums"). We agree that such forum is
convenient to us and we submit to such jurisdiction and waive any objections to
jurisdiction or venue. Should we commence an action in any other forum, we waive
any right to oppose your motion or application to transfer such proceeding to a
court in the Acceptable Forum.

                                       3
<PAGE>

                                    Very truly yours,

                                    --------------------------------
                                    Michael S. Manahan, individually

[Notarial acknowledgement]

                                       4THIS WARRANT AND THE SHARES ISSUABLE  HEREUNDER HAVE NOT BEEN  REGISTERED  UNDER
THE  SECURITIES  ACT OF  1933,  AS  AMENDED,  AND MAY NOT BE  SOLD,  PLEDGED  OR
OTHERWISE  TRANSFERRED WITHOUT AN EFFECTIVE  REGISTRATION THEREOF UNDER SUCH ACT
OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY  SATISFACTORY TO THE
CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.

                            WARRANT TO PURCHASE STOCK

Corporation:            PracticeXpert, Inc., a Nevada corporation

Number of Shares:       900,000

Class of Stock:         Common Stock, par value $0.001 per share

Exercise Price:         $0.30 per share

Issue Date:             June 1, 2005

Expiration Date:        June 1, 2015

      THIS WARRANT  CERTIFIES  THAT,  for good and valuable  consideration,  the
receipt of which is hereby acknowledged, MERIDIAN COMMERCIAL HEALTHCARE FINANCE,
LLC,  a  California  limited  liability  company,   or  its  permitted  assignee
("Holder"),  is entitled to purchase the number of fully paid and  nonassessable
shares  of the  class of  securities  (the  "Shares")  of the  corporation  (the
"Company") at the exercise  price (the  "Warrant  Price") all as set forth above
and as adjusted pursuant to Article 2 of this warrant, subject to the provisions
and upon the terms and conditions set forth in this warrant.

ARTICLE 1. EXERCISE.

      1.1 Method of Exercise.  Holder may exercise this warrant,  in whole or in
part,  by  delivering  this  warrant and a duly  executed  Notice of Exercise in
substantially  the form  attached as Appendix 1 to the  principal  office of the
Company.  Unless Holder is exercising the conversion  right set forth in Section
1.2,  Holder shall also deliver to the Company a check for the Warrant Price for
the Shares being purchased.

      1.2 Conversion  Right.  In lieu of exercising this warrant as specified in
Section 1.1,  Holder may from time to time convert this warrant,  in whole or in
part,  into a number of Shares  determined by  multiplying  the number of shares
issuable upon exercise of this warrant by a fraction, (a) the numerator of which
is the fair market value of one Share minus the Warrant  Price of one Share,  by
(b) the fair  market  value of one Share.  The fair  market  value of the Shares
shall be determined pursuant to Section 1.3.

      1.3 Fair  Market  Value.  If the Shares are traded  regularly  in a public
market,  the fair market value of the Shares  shall be the closing  price of the
Shares (or the closing  price of the  Company's  stock into which the Shares are
convertible)  reported for the business day  immediately  before Holder delivers
its Notice of Exercise to the Company. If the Shares are not regularly traded in
a public market,  then the fair market value of each of the Shares shall be each
Share's  Equity Value.  "Equity Value" per Share shall be determined by dividing
(a) the excess of the  Enterprise  Value over Funded Debt,  by (b) the aggregate
number of issued  and  outstanding  shares of Common  Stock of the  Company on a
fully-diluted basis. For purposes of this Section 1.3, the following terms shall
have the following meanings:

                                       1
<PAGE>

            1.3.1 "Adjusted Net Income" shall mean net income of the Company for
any  period,  excluding  any  non-recurring  or  extraordinary  gains and losses
occurring in such period,  but  normalized  for  historical  uncollectible  debt
expenses.

            1.3.2  "EBITDA"  shall mean  Adjusted Net Income of the Company plus
interest,  tax,  depreciation and amortization  expenses for a twelve (12) month
trailing period.

            1.3.3 "Enterprise  Value" shall mean the Company's EBITDA multiplied
times seven (7).

            1.3.4 "Funded Debt" shall mean all  indebtedness  obligations of the
Company except trade payables  incurred by the Company in the ordinary course of
business.

      1.4  Delivery  of  Certificate  and New  Warrant.  Promptly  after  Holder
exercises  or  converts  this  warrant,  the  Company  shall  deliver  to Holder
certificates  for the Shares  acquired  and, if this  warrant has not been fully
exercised  or  converted  and has not expired,  a new warrant  representing  the
Shares not so acquired.

      1.5   Replacement   of  Warrants.   On  receipt  of  evidence   reasonably
satisfactory  to the Company of the loss,  theft,  destruction  or mutilation of
this warrant and, in the case of loss,  theft or destruction,  on delivery of an
indemnity  agreement  reasonably  satisfactory in form and amount to the Company
or, in the case of mutilation,  on surrender and  cancellation  of this warrant,
the Company at its expense shall execute and deliver, in lieu of this warrant, a
new warrant of like tenor.

                                       2
<PAGE>

      1.6 Put Right. In the event that the Company's  shares of common stock are
not listed for  quotation  on a recognized  national  securities  exchange,  the
Nasdaq  National  Market  (or  a  similar  national   quotation   system),   the
over-the-counter  electronic  bulletin  board or the Pink Sheets  (collectively,
"Public  Markets"),  at Holder's option, in lieu of exercising its rights as set
forth in Section 1.1 or Section 1.2,  Holder shall have the right to require the
Company to purchase  this warrant,  or the Shares  issuable upon the exercise of
this warrant (the "Put  Right"),  for an aggregate  purchase  price equal to the
number of Shares issued and issuable upon exercise of this warrant multiplied by
Equity  Value (the "Put  Price").  Holder may  exercise the Put Right at anytime
during the term of this warrant. The Company shall pay the purchase price to the
Holder  within  seven (7) days  after  receipt  of  Holder's  written  notice of
Holder's  decision to exercise the Put Right;  provided,  that in the event that
Holder's  notice is provided less than seven (7) days prior to the closing of an
Acquisition,  the Company  shall make the payment of the Put Price to the Holder
on the day before the date of the closing of the Acquisition.

      1.7 Purchase  Rights.  If at any time the Company grants,  issues or sells
any  options,  convertible  securities  or rights to purchase  stock,  warrants,
securities or other  property pro rata to the record holders of any Common Stock
(the  "Purchase  Rights"),  then the Holder of this warrant shall be entitled to
acquire,  upon the terms  applicable  to such  Purchase  Rights,  the  aggregate
Purchase  Rights which Holder could have acquired if such Holder held the number
of Shares acquirable upon complete exercise of this warrant  immediately  before
the date on which a record  is taken  for the  grant,  issuance  or sale of such
Purchase Rights, or, if no such record is taken, the date as of which the record
holders of the Common Stock are to be determined for the grant, issue or sale of
such Purchase Rights.

      1.8  Effect  of  Sale,   Merger,   or   Consolidation   of  the   Company.

            1.8.1 "Acquisition." For the purpose of this warrant,  "Acquisition"
means any sale, license, or other disposition of all or substantially all of the
assets (including  intellectual property) of the Company, or any reorganization,
consolidation,  or merger of the  Company  where the  holders  of the  Company's
securities  before  the  transaction  beneficially  own  less  than  50%  of the
outstanding voting securities of the surviving entity after the transaction.

            1.8.2 Assumption of Warrant.  If upon the closing of any Acquisition
the successor entity assumes the obligations of this warrant,  then this warrant
shall be  exercisable  for the same  securities,  cash, and property as would be
payable for the Shares issuable upon exercise of the unexercised portion of this
warrant  as if  such  Shares  were  outstanding  on  the  record  date  for  the
Acquisition  and  subsequent  closing.  The  Warrant  Price  shall  be  adjusted
accordingly.  The Company  shall use  reasonable  efforts to cause the surviving
corporation to assume the obligations of this warrant.

            1.8.3  Nonassumption.  If upon the  closing of any  Acquisition  the
successor entity does not assume the obligations of this warrant, and Holder has
not otherwise  exercised this warrant in full,  then Holder shall have the right
to deem this warrant to have been  automatically  converted  pursuant to Section
1.2 and thereafter Holder shall participate in the Acquisition on the same terms
as other holders of the same class of securities of the Company.

ARTICLE 2. ADJUSTMENTS TO THE SHARES.

      2.1 Reclassification, Exchange or Substitution. Upon any reclassification,
exchange,  substitution,  or other event that  results in a change of the number
and/or class of the  securities  issuable  upon  exercise or  conversion of this
warrant,  Holder shall be entitled to receive,  upon  exercise or  conversion of
this warrant,  the number and kind of securities  and property that Holder would
have  received  for the Shares if this  warrant had been  exercised  immediately

                                       3
<PAGE>

before  such  reclassification,  exchange,  substitution,  or other  event.  The
Company or its successor  shall  promptly issue to Holder a new warrant for such
new securities or other property.  The new warrant shall provide for adjustments
which shall be as nearly  equivalent as may be  practicable  to the  adjustments
provided for in this Article 2 including, without limitation, adjustments to the
Warrant Price and to the number of securities or property issuable upon exercise
of the new warrant.  The provisions of this Section 2.1 shall similarly apply to
successive reclassifications, exchanges, substitutions, or other events.

      2.2  Adjustments  for  Combinations,  Etc. If the  outstanding  Shares are
combined or consolidated, by reclassification or otherwise, into a lesser number
of  shares,  the  Warrant  Price  shall  be  proportionately  increased.  If the
outstanding  Shares  are  combined  or  consolidated,   by  reclassification  or
otherwise,  into a  greater  number  of  shares,  the  Warrant  Price  shall  be
proportionately decreased.

      2.3 Adjustments for Diluting  Issuances.  The Warrant Price and the number
of Shares issuable upon exercise of this warrant shall be subject to adjustment,
from time to time, in the manner set forth on Exhibit A in the event of Diluting
Issuances (as defined on Exhibit A).

      2.4 No Impairment.  The Company shall not, by amendment of its Articles of
Incorporation or through a  reorganization,  transfer of assets,  consolidation,
merger, dissolution, issue, or sale of securities or any other voluntary action,
avoid or seek to avoid the  observance or  performance of any of the terms to be
observed or performed under this warrant by the Company,  but shall at all times
in good faith assist in carrying out all the provisions of this Article 2 and in
taking all such action as may be necessary or  appropriate  to protect  Holder's
rights under this Article against impairment.

      2.5  Certificate as to  Adjustments.  Upon each  adjustment of the Warrant
Price, the Company at its expense shall promptly  compute such  adjustment,  and
furnish Holder with a certificate of its Chief  Financial  Officer setting forth
such adjustment and the facts upon which such  adjustment is based.  The Company
shall,  upon written  request,  furnish  Holder a certificate  setting forth the
Warrant  Price in effect  upon the date  thereof  and the series of  adjustments
leading to such Warrant Price.

ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

      3.1  Representations  and  Warranties.  The Company hereby  represents and
warrants to the Holder as follows:

            (a) All Shares which may be issued upon the exercise of the purchase
right  represented by this warrant,  and all securities,  if any,  issuable upon
conversion of the Shares,  shall,  upon issuance,  be duly  authorized,  validly
issued,  fully paid and  nonassessable,  and free of any liens and  encumbrances
except for  restrictions  on transfer  provided  for herein or under  applicable
federal and state securities laws.

      3.2 Notice of Certain Events.  If the Company  proposes at any time (a) to
declare any dividend or  distribution  upon its common  stock,  whether in cash,
property, stock, or other securities and whether or not a regular cash dividend;
(b) to offer for  subscription pro rata to the holders of any class or series of
its stock any additional shares of stock of any class or series or other rights;
(c) to effect any  reclassification  or recapitalization of common stock; or (d)
to merge or  consolidate  with or into any other  corporation,  or sell,  lease,
license,  or convey all or  substantially  all of its assets,  or to  liquidate,
dissolve or wind up, then, in connection with each such event, the Company shall

                                       4
<PAGE>

give  Holder  (1) at least 25 days prior  written  notice of the date on which a
record will be taken for such dividend,  distribution,  or  subscription  rights
(and  specifying  the date on which the holders of common stock will be entitled
thereto) or for  determining  rights to vote,  if any, in respect of the matters
referred to in (a) and (b) above; and (2) in the case of the matters referred to
in (c) and (d) above at least 25 days prior written  notice of the date when the
same will take place  (and  specifying  the date on which the  holders of common
stock will be entitled to exchange  their common stock for  securities  or other
property deliverable upon the occurrence of such event).

      3.3  Information  Rights.  So long as the Holder holds this warrant and/or
any of the Shares,  the Company shall  deliver to the Holder (a) promptly  after
mailing,  copies of all  communiques  to the  shareholders  of the Company,  (b)
within one  hundred and five (105) days after the end of each fiscal year of the
Company,  the annual audited  financial  statements of the Company  certified by
independent  public  accountants of recognized  standing,  (c) within fifty (50)
days after the end of each of the first three  quarters of each fiscal year, the
Company's quarterly,  unaudited financial statements, and (d) within thirty (30)
days after the end of each quarter of each fiscal year, a  capitalization  table
showing all issued and outstanding  (i) capital stock of the Company,  organized
by class  and  series,  and (b) all  options,  warrants  and other  purchase  or
acquisition  rights with respect to any class or series of capital  stock of the
Company held by any person.

      3.4 Registration.

            (a) Definitions.

                  For purposes of this Section 3.4 the following  terms have the
following definitions:

                  "Registrable  Stock"  means (i) all Shares  which are issuable
pursuant to this warrant,  whether or not the warrant has in fact been exercised
and  whether  or not such  Shares  have in fact  been  issued,  (ii) all  Shares
acquired  by Holder  pursuant  to this  warrant,  and (iii) any shares of Common
Stock,  whether or not such shares of Common Stock have in fact been issued, and
stock  or  other   securities  of  the  Company  issued  in  a  stock  split  or
reclassifications  of,  or a stock  dividend  or other  distribution  on,  or in
substitution or exchange for, or otherwise in connection with, such Shares.

                  "Commission"   means   the  U.S.   Securities   and   Exchange
Commission.

                  "participating  holders"  means holders of  Registrable  Stock
included in a registration  statement filed with the Commission pursuant to this
Section 3.4.

                  "Securities Act" means the Securities Act of 1933, as amended.

            (b) Incidental  Registration.  Each time the Company shall determine
to file a  registration  statement  under the  Securities  Act (other than (i) a
post-effective amendment to the Company's Form SB-2 Registration Statement (File
No.  333-117126),  or (ii)  on Form  S-8 or Form  S-4) in  connection  with  the
proposed  offer and sale for money of any of its  securities  by it or by any of
its security holders,  the Company will give written notice of its determination
to all holders of  Registrable  Stock at least ten (10) days prior to the filing
of such  registration  statement.  Upon the  written  request of a holder of any
Registrable  Stock,  within ten (10) days after  receipt of the  above-described
notice from the Company,  the Company will cause all such Registrable Stock, the
holders of which have so requested  registration thereof, to be included in such
registration statement,  all to the extent requisite to permit the sale or other
disposition by the prospective  seller or sellers of the Registrable Stock to be

                                       5
<PAGE>

so  registered  in accordance  with the terms of the proposed  offering.  If the
registration  statement is to cover an  underwritten  distribution,  the Company
shall  use its best  efforts  to  cause  the  Registrable  Stock  requested  for
inclusion  pursuant to this Section 3.4(b) to be included in the underwriting on
the same terms and conditions as the securities otherwise being sold through the
underwriters.  In the event of a firm commitment  underwriting,  if the managing
underwriter  of such offering  shall advise holders in writing that, in its good
faith opinion,  distribution of a specified portion of the securities  requested
to be included in the registration  statement would materially  adversely affect
the  distribution of such  securities by increasing the aggregate  amount of the
offering  in excess of the  maximum  amount of  securities  which such  managing
underwriter  believes can reasonably be sold in the  contemplated  distribution,
then the securities to be included in the registration  shall be included in the
following  order:  (1) first,  the securities the Company proposes to include in
the  underwritten  offering,  (2)  second,  Registrable  Stock  requested  to be
included in such  registration  by holders of Registrable  Stock,  on a pro rata
basis, and (3) third, all other shares of securities requested to be included by
any other  security  holder of the  Company.  The  Company  shall  maintain  the
effectiveness  of any such  registration  statement  until the date which is the
later to occur of (i) the  expiration  of any  such  public  offering,  and (ii)
twelve  (12)  months  from the date  that any  such  registration  statement  is
declared effective by the Commission.

            (c) Expenses of Registration. All expenses incident to the Company's
performance of or compliance with this warrant,  including,  without limitation,
the  following  shall  be  borne  by the  Company,  regardless  of  whether  the
registration statement becomes effective:

                  (i) All  registration  and filing fees  (including  those with
respect  to  filings  required  to be made  with  the  National  Association  of
Securities Dealers, Inc.);

                  (ii) Fees and expenses of  compliance  with all  securities or
blue sky laws (including fees and  disbursements of counsel for the underwriters
or  participating  holders in  connection  with blue sky  qualifications  of the
Registrable Stock and in determination of their eligibility for investment under
the laws of such  jurisdictions  as the managing  underwriters or  participating
holders of a majority of the Registrable Stock being sold may designate);

                  (iii) Printing, messenger,  telephone,  facsimile and delivery
expenses;

                  (iv) Fees and  disbursements  of counsel for the Company,  and
the underwriters;

                  (v) Fees and disbursements of all independent certified public
accountants  of the Company  (including  the  expenses of any special  audit and
"comfort" letters required by or incident to such performance);

                  (vi)  Fees  and   disbursements  of  underwriters   (excluding
discounts, commissions or fees of underwriters, selling brokers, dealer managers
or similar securities industry professionals relating to the distribution of the
Registrable Stock or legal expenses of any person other than the Company and the
selling holders); and

                  (vii)  Fees and  expenses  of other  persons  retained  by the
Company.

                        The  Company  will,  in  any  event,  pay  its  internal
expenses  (including  without  limitation,  all  salaries  and  expenses  of its
officers and employees  performing legal or accounting  duties),  the expense of
any annual audit, the fees and expenses  incurred in connection with the listing
of the securities to be registered on each securities  exchange on which similar
securities  issued by the Company are then  listed,  rating  agency fees and the
fees and  expenses of any person,  including  special  experts,  retained by the
Company.

                                       6
<PAGE>

            (d) Indemnification.

                  (i)  The  Company  hereby  agrees  to  indemnify  each  of the
participating   holders  of  Registrable  Stock  included  on  any  registration
statement and their officers and directors and each person, if any, who controls
any  thereof  within the meaning of Section 15 of the  Securities  Act and their
respective  successors against all claims,  losses,  damages and liabilities (or
actions in respect  thereof),  joint or several,  arising out of or based on any
untrue  statement (or alleged untrue  statement) of a material fact contained in
any registration statement,  preliminary or final prospectus,  or other document
incident  to any  such  registration,  qualification  or  compliance  (or in any
related  registration  statement,  notification or the like) or any omission (or
alleged omission) to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading,  or any violation by
the  Company of any rule or  regulation  promulgated  under the  Securities  Act
applicable  to the  Company and  relating to action or inaction  required of the
Company in connection with any such  registration,  qualification or compliance,
and to  reimburse  the holders of  Registrable  Stock  (including  officers  and
directors  of the same and  controlling  persons)  for any  legal  and any other
expenses  reasonably  incurred in connection with investigating or defending any
such claim,  loss,  damage,  liability or action,  provided,  however,  that the
Company  will not be liable in any such case to the extent  that any such claim,
loss,  damage or liability  arises out of or is based on any untrue statement or
omission based upon written  information  furnished to the Company by holders of
Registrable  Stock in an  instrument  duly  executed  by them and  stated  to be
specifically for use therein.

                  (ii)  Participating  holders of Registrable Stock whose shares
are included in a registration  statement,  severally and not jointly,  agree to
indemnify the Company and its officers and  directors  and each person,  if any,
who controls any thereof  within the meaning of Section 15 of the Securities Act
and  their  respective  successors  against  all  claims,  losses,  damages  and
liabilities (or actions in respect thereof), joint or several, arising out of or
based on any untrue  statement of a material fact contained in any  registration
statement,  preliminary or final  prospectus or other  document  incident to any
such registration,  qualification or compliance  relating to the Warrants or the
securities  purchased  pursuant to the Warrants (or in any related  registration
statement,  notification  or the like) or any omission (or alleged  omission) to
state therein a material fact required to be stated therein or necessary to make
the  statements  therein not  misleading,  and to reimburse the Company and each
other person  indemnified  pursuant to this Section 3.4(d) for any legal and any
other expenses reasonably incurred in connection with investigating or defending
any such claim, loss, damage, liability or action; provided,  however, that this
Section  3.4(d) shall apply only if (and only to the extent that) such statement
or  omission  was  made  in  reliance  upon  information   (including,   without
limitation, written negative responses to inquiries) furnished to the Company in
writing in an instrument duly executed by  participating  holders of Registrable
Stock  and  stated  to be  specifically  for use in such  prospectus,  or  other
document (or related  registration  statement,  notification or the like) or any
amendment or supplement  thereto;  provided  further,  that in no case shall any
participating  holder of  Registrable  Stock be  responsible  for any  amount in
excess of the amount of net proceeds received by such participating holders from
the offering of the securities.

                  (iii) Promptly after receipt by an indemnified party of notice
of the commencement of any action or proceeding involving a claim referred to in
this Section 3.4(d), such indemnified party shall, if a claim in respect thereof
is to be made against an indemnifying  party,  give written notice to the latter
of the commencement of such action;  provided,  however, that the failure of any
indemnified  party to give  notice as  provided  herein  shall not  relieve  the
indemnifying  party of its obligations under the preceding  subdivisions of this
Section  3.4(d),  except to the extent that the  indemnifying  party is actually
prejudiced  by such failure to give  notice.  In case any such action is brought

                                       7
<PAGE>

against an indemnified  party,  unless in such  indemnified  party's  reasonable
judgment a conflict  of  interest  between  such  indemnified  and  indemnifying
parties  may exist in respect of such  claim,  the  indemnifying  party shall be
entitled to participate in and to assume the defense  thereof,  jointly with any
other indemnifying party similarly notified, to the extent that the indemnifying
party may wish, with counsel reasonably  satisfactory to such indemnified party,
and after notice from the indemnifying  party to such  indemnified  party of its
election so to assume the defense thereof,  the indemnifying  party shall not be
liable to such  indemnified  party for any legal or other expenses  subsequently
incurred  by the  latter in  connection  with the  defense  thereof  other  than
reasonable costs of  investigation.  If, in the indemnified  party's  reasonable
judgment a conflict  of  interest  between  such  indemnified  and  indemnifying
parties may exist in respect of such claim, the indemnified party may assume the
defense of such claim,  jointly with any other indemnified party that reasonably
determines such conflict of interest to exist, and the indemnifying  party shall
be liable to such indemnified parties for the reasonable legal fees and expenses
of one  counsel  for  all  such  indemnified  parties  and  for  other  expenses
reasonably  incurred  in  connection  with the defense  thereof  incurred by the
indemnified  party.  No  indemnifying  party  shall,  without the consent of the
indemnified party, consent to entry of any judgment or enter into any settlement
of any such action which does not include as an  unconditional  term thereof the
giving by the claimant or plaintiff to such indemnified  party of a release from
all liability, or a covenant not to sue, in respect of such claim or litigation.
No  indemnified  party shall  consent to entry of any judgment or enter into any
settlement  of any such  action  the  defense  of which has been  assumed  by an
indemnifying party without the consent of such indemnifying party.

                  (iv)   Indemnification   and  contribution   similar  to  that
specified in this Section 3.4(d) (with appropriate modifications) shall be given
by the Company and each participating  holder of Registrable Stock included in a
registration  statement  with  respect  to any  required  registration  or other
qualification of Registrable  Stock under any Federal or state law or regulation
of any governmental authority, other than the Securities Act.

                  (v) The indemnification  required by this Section 3.4(d) shall
be made by  periodic  payments  of the amount  thereof  during the course of the
investigation  or defense,  as and when bills are  received  or  expense,  loss,
damage or liability is incurred.

                  (vi)  If the  indemnification  provided  for in  this  Section
3.4(e)  from the  indemnifying  party is  unavailable  to an  indemnified  party
hereunder in respect of any losses, claims,  damages,  liabilities,  or expenses
referred to herein,  then the indemnifying  party, in lieu of indemnifying  such
indemnified  party,  shall  contribute  to the  amount  paid or  payable by such
indemnified  party as a result  of  losses,  claims,  damages,  liabilities,  or
expenses in such  proportion as is  appropriate to reflect the relative fault of
the  indemnifying  party and  indemnified  party in connection  with the actions
which resulted in such losses,  claims,  damages,  liabilities,  or expenses, as
well as any other relevant equitable considerations.  The relative fault of such
indemnifying  party and  indemnified  party shall be determined by reference to,
among other  things,  whether any action in  question,  including  any untrue or
alleged untrue  statement of a material fact or omission or alleged  omission to
state a material fact, has been made by, or relates to information  supplied by,
such indemnifying  party or indemnified party, and the parties' relative intent,
knowledge,  access to  information,  and  opportunity to correct or prevent such
action. The amount paid or payable by a party as a result of the losses, claims,
damages,  liabilities, and expenses referred to above shall be deemed to include
any  legal  or other  fees or  expenses  reasonably  incurred  by such  party in

                                       8
<PAGE>

connection with any investigation or proceeding. In no event shall the liability
of any person or entity hereunder be greater in amount than the dollar amount of
the proceeds  received by such person or entity upon the sale of the Registrable
Stock giving rise to such contribution obligation. The parties hereto agree that
it would not be just and  equitable  if  contribution  pursuant to this  Section
3.4(d)(vi)  were  determined  by pro rata  allocation  or by any other method of
allocation  which  does not  take  into  account  the  equitable  considerations
referred  to  in  this  Section  3.4(d)(vi).  No  person  guilty  of  fraudulent
misrepresentation  (within the meaning of Section 11(f) of the  Securities  Act)
shall be entitled to  contribution  from any person or entity who was not guilty
of such fraudulent misrepresentation.

            (e) Assignment of Rights; Termination. The rights granted under this
Section  3.4  may be  assigned  to the  transferee  of  any  of the  Warrant  or
Registrable Stock

ARTICLE 4. MISCELLANEOUS.

      4.1 Term: Notice of Expiration. This warrant is exercisable in whole or in
part,  at any time and from time to time on or after  the  Issue  Date and on or
before  the  Expiration  Date set  forth  above.  If this  warrant  has not been
exercised  prior to the  Expiration  Date,  this warrant shall be deemed to have
been  automatically  exercised on the Expiration  Date by "cashless"  conversion
pursuant to Section 1.2.

      4.2  Legends.  This warrant and the Shares (and the  securities  issuable,
directly  or  indirectly,  upon  conversion  of the  Shares,  if any)  shall  be
imprinted with a legend in substantially the following form:

THIS  SECURITY HAS NOT BEEN  REGISTERED  UNDER THE  SECURITIES  ACT OF 1933,  AS
AMENDED,  AND MAY NOT BE SOLD,  PLEDGED  OR  OTHERWISE  TRANSFERRED  WITHOUT  AN
EFFECTIVE  REGISTRATION  THEREOF  UNDER SUCH ACT OR  PURSUANT  TO RULE 144 OR AN
OPINION OF COUNSEL  REASONABLY  SATISFACTORY  TO THE CORPORATION AND ITS COUNSEL
THAT SUCH REGISTRATION IS NOT REQUIRED.

      4.3  Compliance  with  Securities  Laws on Transfer.  This warrant and the
Shares  issuable  upon  exercise of this warrant (and the  securities  issuable,
directly  or  indirectly,  upon  conversion  of the  Shares,  if any) may not be
transferred or assigned in whole or in part without  compliance  with applicable
federal  and  state  securities  laws  by  the  transferor  and  the  transferee
(including,  without  limitation,  the  delivery  of  investment  representation
letters and legal opinions reasonably  satisfactory to the Company). The Company
shall not require  Holder to provide an opinion of counsel if the transfer is to
an affiliate of Holder that is an  "accredited  investor"  within the meaning of
Rule 501 of the  Securities  Act, or if there is no material  question as to the
availability  of  current  information  as  referenced  in Rule  144(c),  Holder
represents  that it has complied with Rule 144(d) and (e) in reasonable  detail,
the selling  broker  represents  that it has complied with Rule 144(f),  and the
Company is  provided  with a copy of  Holder's  notice of  proposed  sale.  With
respect to any transfer by any Holder pursuant to Rule 144, to the extent that a
legal opinion is required to effect such  transfer by Holder,  the Company shall
deliver an opinion of its counsel (at the Company's  expense),  as required,  to
any broker or  transfer  agent to the effect that the  proposed  transfer by the
Holder may be effected pursuant to Rule 144.

      4.4 Transfer  Procedure.  Subject to the provisions of Section 4.3, Holder
may transfer all or part of this warrant or the Shares issuable upon exercise of
this  warrant  (or  the  securities  issuable,   directly  or  indirectly,  upon
conversion of the Shares, if any) by giving the Company notice of the portion of
the warrant  being  transferred  setting  forth the name,  address and  taxpayer
identification  number of the  transferee and  surrendering  this warrant to the
Company  for  reissuance  to the  transferee(s)  (and  Holder,  if  applicable);
provided,  however,  that Holder may transfer all or part of this warrant to its
affiliates at any time without notice to the Company,  and such affiliate  shall
then be entitled to all the rights of Holder  under this warrant and any related

                                       9
<PAGE>

agreements,  and the Company  shall  cooperate  fully in ensuring that any stock
issued upon exercise of this warrant is issued in the name of the affiliate that
exercises this warrant.  The term  "affiliate"  as used herein shall mean,  with
respect to Holder,  any person or entity which directly or indirectly  controls,
is controlled by, or is under common control with, Holder. The term "control" as
used herein, shall mean the possession,  directly or indirectly, of the power to
direct or cause the  direction  of the  management  and  policies of a person or
entity, whether through ownership of voting securities,  by contract,  acting as
an officer,  director or manager or otherwise.  The terms and conditions of this
warrant shall inure to the benefit of, and be binding upon,  the Company and the
holders hereof and their respective permitted successors and assigns. Unless the
Company is filing financial  information with the SEC pursuant to the Securities
Exchange Act of 1934, the Company shall have the right to refuse to transfer any
portion of this warrant to any person who directly competes with the Company.

      4.5 Notices.  All notices and other communications to a party hereto shall
be in writing.  All such notices and communications shall be deemed to have been
duly given, when delivered by hand, if personally  delivered;  when delivered by
courier,  if delivered by commercial  overnight courier service; if mailed, five
(5) business days after being deposited in the mail,  postage  prepaid;  and, if
faxed,  when  transmission  is  confirmed.  All notices  shall be  addressed  as
follows:

      To Holder:        Meridian Commercial Healthcare Finance, LLC
                        4320 La Jolla Village Drive, Suite 250
                        San Diego, CA 92122
                        Attn.: Ron Pituch
                        Fax: (858) 200-2051

      To Company:       PracticeXpert, Inc.
                        10833 Washington Boulevard
                        Culver City, CA  90232
                        Attn.: Michael Manahan
                        Fax: (310) 815-3507

      4.6 Amendments.  This warrant and any term hereof may be changed,  waived,
discharged  or terminated  only by an instrument in writing  signed by the party
against which  enforcement of such change,  waiver,  discharge or termination is
sought.

      4.7  Attorneys'  Fees.  In the event of any  dispute  between  the parties
concerning  the terms and  provisions of this warrant,  the party  prevailing in
such  dispute  shall be  entitled  to  collect  from the  other  party all costs
incurred in such dispute, including reasonable attorneys' fees.

                                       10
<PAGE>

      4.8  Governing  Law.  This warrant  shall be governed by and  construed in
accordance  with the laws of the State of  California,  without giving effect to
its principles regarding conflicts of law.

                                    PRACTICEXPERT, INC.
                                    a Nevada corporation

                                    By:
                                       ---------------------------------
                                       Michael Manahan
                                       Chief Financial Officer

ACCEPTED AND AGREED TO BY:

MERIDIAN COMMERCIAL HEALTHCARE FINANCE, LLC
a Nevada limited liability company

By:
   ---------------------------------
Name:
     -------------------------------
Title:
      ------------------------------

                                       11
<PAGE>

                                   APPENDIX 1

                               NOTICE OF EXERCISE

      1. The undersigned hereby elects to purchase  ______________ shares of the
common  stock,  par value  $0.001 per share,  of  PracticeXpert,  Inc., a Nevada
corporation, pursuant to the terms of the attached warrant, and tenders herewith
payment of the purchase price of such shares in full.

      1. The  undersigned  hereby  elects to convert the  attached  warrant into
shares of common stock, par value $0.001 per share, of  PracticeXpert,  Inc., in
the manner  specified in the warrant.  This conversion is exercised with respect
to ______________ of the shares covered by the warrant.

      [Strike paragraph that does not apply.]

      2. Please issue a certificate or certificates  representing said shares in
the name of the undersigned or in such other name as is specified below:

      Meridian Commercial Healthcare Finance, LLC
      ________________________________________
      ________________________________________
      ________________________________________

      3. The  undersigned  represents  it is acquiring the shares solely for its
own  account and not as a nominee for any other party and not with a view toward
the  resale  or  distribution  thereof  except  in  compliance  with  applicable
securities laws.

MERIDIAN COMMERCIAL HEALTHCARE FINANCE, LLC,

------------------------------------------------
(Signature)

------------------------------------------
(Date)

                                       1
<PAGE>

                                    EXHIBIT A

                   MERIDIAN COMMERCIAL HEALTHCARE FINANCE, LLC

                             ANTI-DILUTION AGREEMENT

      This  Anti-Dilution  Agreement  is entered into as of the 1st day of June,
2005, by and between Meridian Commercial  Healthcare Finance,  LLC ("Purchaser")
and PracticeXpert, Inc. ("the Company").

                                    RECITALS

      A. Concurrently with the execution of this  Anti-Dilution  Agreement,  the
Purchaser  is  purchasing  from the  Company a Warrant  to  Purchase  Stock (the
"Warrant") pursuant to which Purchaser has the right to acquire from the Company
the Shares (as defined in the Warrant).

      B. By this Anti-Dilution  Agreement,  the Purchaser and the Company desire
to set forth the  adjustment  in the number of Shares  issuable upon exercise of
the Warrant as a result of a Diluting Issuance (as defined below).

      C. Capitalized  terms used herein shall have the same meaning as set forth
in the Warrant.

            NOW, THEREFORE,  in consideration of the mutual promises,  covenants
and  conditions  hereinafter  set forth,  the parties  hereto  mutually agree as
follows:

      1. Definitions.  As used in this  Anti-Dilution  Agreement,  the following
terms have the following respective meanings:

            (a) "Option"  means any right,  option or warrant to subscribe  for,
purchase or otherwise acquire common stock or Convertible Securities.

            (b)  "Convertible  Securities"  means any evidences of indebtedness,
shares of stock or other securities  directly or indirectly  convertible into or
exchangeable for common stock.

            (c) "Issue" means to grant, issue, sell, assume or fix a record date
for determining  persons entitled to receive any security  (including  Options),
whichever of the foregoing is the first to occur.

            (d)  "Additional  Common  Shares" means all common stock  (including
reissued shares) Issued (or deemed to be issued pursuant to Section 2) after the
date of the Warrant.  Additional  Common Shares does not include,  however,  any
common  stock Issued in a  transaction  described in Sections 2.1 and 2.2 of the
Warrant;  any common stock Issued upon conversion of preferred stock outstanding
on the date of the Warrant;  the Shares;  or common stock Issued as incentive or
in a non-financing transaction to employees,  officers, directors or consultants
to the Company.

      2. Deemed Issuance of Additional Common Shares. The shares of common stock
ultimately  Issuable upon exercise of an Option  (including the shares of common
stock ultimately Issuable upon conversion or exercise of a Convertible  Security
Issuable  pursuant  to an  Option)  are  deemed to be Issued  when the Option is
Issued.  The shares of common  stock  ultimately  Issuable  upon  conversion  or
exercise of a Convertible  Security  (other than a Convertible  Security  Issued
pursuant to an Option) shall be deemed  Issued upon Issuance of the  Convertible
Security.  The maximum  amount of common stock  Issuable is  determined  without
regard to any future  adjustments  permitted  under the instrument  creating the
Options or Convertible Securities.

                                      B-1
<PAGE>

      3. Adjustment of Warrant Price and Warrant Shares for Diluting Issuances.

            3.1 Full Ratchet Price Adjustment.  If the Company issues Additional
Common Shares after the date of the Warrant and the consideration per Additional
Common Share  (determined  pursuant to Section 9) is less than the Warrant Price
in effect  immediately  before  such  Issue (a  "Diluting  Issuance"),  then the
Warrant  Price in  effect  immediately  before  such  Issue  shall  be  reduced,
concurrently with such Issue, to a price (calculated to the nearest hundredth of
a cent)  equal to the  lowest  per  share  price to be paid for each  Additional
Common Share in such Issue.

            3.2 Securities Deemed  Outstanding.  For the purpose of this Section
3,  all  securities  Issuable  upon  exercise  of  any  outstanding  Convertible
Securities or Options,  Warrants,  or other rights to acquire  securities of the
Company shall be deemed to be outstanding.

            3.3  Adjustment  of Shares  Purchasable.  To the  extent a  Diluting
Issuance  occurs,  the number of shares of Common Stock  purchasable  under this
warrant  shall be  increased to that number of Shares equal to (a) the number of
Shares  purchasable  under  this  warrant  immediately  prior  to  the  Diluting
Issuance,  multiplied  by (b) a fraction,  (i) the numerator of which equals the
Warrant Price prior to adjustment under Section 3.1, and (ii) the denominator of
which equals the Warrant Price as adjusted under Section 3.1.

      4. No Adjustment for Issuances  Following Deemed Issuances.  No adjustment
to the Warrant Price shall be made upon the exercise of Options or conversion of
Convertible Securities.

      5.  Adjustment  Following  Changes  in Terms  of  Options  or  Convertible
Securities.  If the  consideration  payable  to, or the  amount of common  stock
Issuable by, the Company increases or decreases,  respectively,  pursuant to the
terms of any outstanding  Options or Convertible  Securities,  the Warrant Price
shall be  recomputed  to reflect such  increase or decrease.  The  recomputation
shall be made as of the  time of the  Issuance  of the  Options  or  Convertible
Securities.  Any changes in the Warrant Price that occurred  after such Issuance
because other  Additional  Common Shares were Issued or deemed Issued shall also
be recomputed.

      6. Recomputation Upon Expiration of Options or Convertible Securities. The
Warrant  Price  computed upon the original  Issue of any Options or  Convertible
Securities,  and any subsequent  adjustments based thereon,  shall be recomputed
when any Options or rights of conversion  under  Convertible  Securities  expire
without having been exercised.  In the case of Convertible Securities or Options
for  common  stock,  the  Warrant  Price  shall  be  recomputed  as if the  only
Additional  Common Shares Issued were the shares of common stock actually Issued
upon the exercise of such securities,  if any, and as if the only  consideration
received  therefor  was the  consideration  actually  received  upon the  Issue,
exercise or conversion of the Options or Convertible Securities.  In the case of
Options for Convertible Securities,  the Warrant Price shall be recomputed as if
the only Convertible  Securities Issued were the Convertible Securities actually
Issued  upon the  exercise  thereof,  if any,  and as if the only  consideration
received  therefor  was  the  consideration  actually  received  by the  Company
(determined  pursuant to Section  9), if any,  upon the Issue of the Options for
the Convertible Securities.

                                      B-2
<PAGE>

      7. Limit on  Readjustments.  No readjustment of the Warrant Price pursuant
to Sections 5 or 6 shall  increase the Warrant Price more than the amount of any
decrease made in respect of the Issue of any Options or Convertible Securities.

      8. 30 Day  Options.  In the case of any Options that expire by their terms
not more than 30 days  after the date of Issue  thereof,  no  adjustment  of the
Warrant  Price  shall be made  until  the  expiration  or  exercise  of all such
Options.

      9. Computation of Consideration. The consideration received by the Company
for the Issue of any Additional Common Shares shall be computed as follows:

            (a) Cash  shall be valued  at the  amount  of cash  received  by the
Corporation,  excluding  amounts paid or payable for accrued interest or accrued
dividends.

            (b) Property.  Property,  other than cash,  shall be computed at the
fair market value  thereof at the time of the Issue as  determined in good faith
by the Board of Directors of the Company.

            (c) Mixed  Consideration.  The  consideration  for Additional Common
Shares Issued together with other property of the Company for consideration that
covers both shall be determined in good faith by the Board of Directors.

            (d)  Options  and  Convertible  Securities.  The  consideration  per
Additional  Common  Share  for  Options  and  Convertible  Securities  shall  be
determined by dividing:

                  (i) the total  amount,  if any,  received or receivable by the
Company for the Issue of the Options or Convertible Securities, plus the minimum
amount of additional  consideration  (as set forth in the  instruments  relating
thereto,  without  regard to any  provision  contained  therein for a subsequent
adjustment  of such  consideration)  payable to the Company upon exercise of the
Options or conversion of the Convertible Securities, by

                  (ii) the maximum  amount of common  stock (as set forth in the
instruments relating thereto,  without regard to any provision contained therein
for a  subsequent  adjustment  of such  number)  ultimately  Issuable  upon  the
exercise of such Options or the conversion of such Convertible Securities.

      10. General.

            10.1 Governing Law. This  Anti-Dilution  Agreement shall be governed
in all respects by the laws of the State of  California as such laws are applied
to  agreements  between  California  residents  entered into and to be performed
entirely within California.

            10.2 Successors and Assigns.  Except as otherwise expressly provided
herein,  the  provisions  hereof  shall  inure to the benefit of, and be binding
upon,  the  successors,  assigns,  heirs,  executors and  administrators  of the
parties hereto.

            10.3 Entire Agreement. Except as set forth below, this Anti-dilution
Agreement and the other documents  delivered pursuant hereto constitute the full
and entire  understanding  and agreement  between the parties with regard to the
subjects hereof and thereof.

                                      B-3
<PAGE>

            10.4 Notices, etc. All notices and other communications  required or
permitted hereunder shall be in writing and shall be mailed by first class mail,
postage  prepaid,  certified  or  registered  mail,  return  receipt  requested,
addressed (a) if to Purchaser at Purchaser's  address as set forth below,  or at
such other address as Purchaser  shall have furnished to the Company in writing,
or (b) if to the Company,  at the Company's  address set forth below, or at such
other address as the Company shall have furnished to the Purchaser in writing.

            10.5  Severability.  In case  any  provision  of this  Anti-Dilution
Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions of this Anti-dilution Agreement shall
not in any way be affected or impaired thereby.

            10.6  Titles  and   Subtitles.   The  titles  of  the  sections  and
subsections of this Agreement are for  convenience of reference only and are not
to be considered in construing this Anti-Dilution Agreement.

            10.7 Counterparts.  This Anti-Dilution  Agreement may be executed in
any number of counterparts, each of which shall be an original, but all of which
together shall constitute one instrument.

PURCHASER                                 ISSUER

MERIDIAN COMMERCIAL HEALTHCARE            PRACTICEXPERT, INC.,
FINANCE, LLC, a Nevada limited            a Nevada corporation
liability company

By:                                       By:
   ---------------------------------         ---------------------------------
Name:                                        Michael Manahan
     -------------------------------         Chief Financial Officer
Title:
      ------------------------------

Address: 4320 LaJolla Village Drive,      Address: 10833 Washington Boulevard
         Suite 250                                 Culver City, CA 90232
         San Diego, CA 92122

                                      B-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]